AVID100 Antibody  (Synonyms: MAB100 Antibody)

AVID100 Antibody (MAB100) is a monoclonal antibody inhibitor targeting EGFR, which can be used to synthesize a novel antibody-drug conjugate (ADC) molecule AVID100. AVID100 Antibody is applicable to relevant research on breast cancer, head and neck cancer, and lung cancer^[1].

Human

AVID100 Antibody (MAB100) binds EGFR with an affinity of approximately 2 nM, acts as a full EGFR antagonist that blocks downstream signaling, and competes with EGF for EGFR binding^[1].
AVID100 induces apoptosis and potent cytotoxicity (with IC₅₀ values correlating with EGFR expression) in MDA-MB-468, H292, and FaDu cancer cells, but does not increase cytotoxicity or apoptosis in normal keratinocytes relative to unconjugated MAB100^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1956  [NCBI]

P00533

ERBB1/EGFR/HER1

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

[AVID100 Antibody]

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Michael J. Thwaites, et al. Abstract 218: AVID100 is an anti-EGFR ADC that promotes DM1-meditated cytotoxicity on cancer cells but not on normal cells. Cancer Res (2019) 79 (13_Supplement): 218.